These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 31648851)

  • 1. Vinflunine/gemcitabine versus carboplatin/gemcitabine as first-line treatment in cisplatin-ineligible patients with advanced urothelial carcinoma: A randomised phase II trial (VINGEM).
    Holmsten K; Jensen NV; Mouritsen LS; Jonsson E; Mellnert C; Agerbæk M; Nilsson C; Moe M; Carus A; Öfverholm E; Lahdenperä O; Brandberg Y; Johansson H; Hellström M; Maase HV; Pappot H; Ullén A
    Eur J Cancer; 2020 Mar; 127():173-182. PubMed ID: 31648851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vinflunine-gemcitabine versus vinflunine-carboplatin as first-line chemotherapy in cisplatin-unfit patients with advanced urothelial carcinoma: results of an international randomized phase II trial (JASINT1).
    De Santis M; Wiechno PJ; Bellmunt J; Lucas C; Su WC; Albiges L; Lin CC; Senkus-Konefka E; Flechon A; Mourey L; Necchi A; Loidl WC; Retz MM; Vaissière N; Culine S
    Ann Oncol; 2016 Mar; 27(3):449-54. PubMed ID: 26673352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA; SOGUG 2011/02): a multicentre, randomised, controlled, open-label, phase 2 trial.
    García-Donas J; Font A; Pérez-Valderrama B; Virizuela JA; Climent MÁ; Hernando-Polo S; Arranz JÁ; Del Mar Llorente M; Lainez N; Villa-Guzmán JC; Mellado B; González Del Alba A; Castellano D; Gallardo E; Anido U; García Del Muro X; Domènech M; Puente J; Morales-Barrera R; Pérez-Gracia JL; Bellmunt J
    Lancet Oncol; 2017 May; 18(5):672-681a. PubMed ID: 28389316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gemcitabine plus carboplatin versus gemcitabine plus oxaliplatin in cisplatin-unfit patients with advanced urothelial carcinoma: a randomised phase II study (COACH, KCSG GU10-16).
    Park I; Kim BS; Lim HY; Kim HJ; Lee HJ; Choi YJ; Park KH; Lee KH; Yoon S; Hong B; Hong JH; Ahn H; Lee JL
    Eur J Cancer; 2020 Mar; 127():183-190. PubMed ID: 31668839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986.
    De Santis M; Bellmunt J; Mead G; Kerst JM; Leahy M; Maroto P; Gil T; Marreaud S; Daugaard G; Skoneczna I; Collette S; Lorent J; de Wit R; Sylvester R
    J Clin Oncol; 2012 Jan; 30(2):191-9. PubMed ID: 22162575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II California Cancer Consortium Trial of Gemcitabine-Eribulin Combination in Cisplatin-Ineligible Patients With Metastatic Urothelial Carcinoma: Final Report (NCI-9653).
    Sadeghi S; Groshen SG; Tsao-Wei DD; Parikh R; Mortazavi A; Dorff TB; Kefauver C; Hoimes C; Doyle L; Quinn DI; Newman E; Lara PN
    J Clin Oncol; 2019 Oct; 37(29):2682-2688. PubMed ID: 31390274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized phase II/III trial assessing gemcitabine/ carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer "unfit" for cisplatin-based chemotherapy: phase II--results of EORTC study 30986.
    De Santis M; Bellmunt J; Mead G; Kerst JM; Leahy M; Maroto P; Skoneczna I; Marreaud S; de Wit R; Sylvester R
    J Clin Oncol; 2009 Nov; 27(33):5634-9. PubMed ID: 19786668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination therapy consisting of gemcitabine, carboplatin, and docetaxel as an active treatment for advanced urothelial carcinoma.
    Tsuruta H; Inoue T; Narita S; Horikawa Y; Saito M; Obara T; Numakura K; Maita S; Satoh S; Tsuchiya N; Habuchi T
    Int J Clin Oncol; 2011 Oct; 16(5):533-8. PubMed ID: 21431341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of gemcitabine, carboplatin, and bevacizumab in patients with advanced unresectable or metastatic urothelial cancer.
    Balar AV; Apolo AB; Ostrovnaya I; Mironov S; Iasonos A; Trout A; Regazzi AM; Garcia-Grossman IR; Gallagher DJ; Milowsky MI; Bajorin DF
    J Clin Oncol; 2013 Feb; 31(6):724-30. PubMed ID: 23341513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The first Slovak experience with second-line vinflunine in advanced urothelial carcinomas.
    Palacka P; Mego M; Obertova J; Chovanec M; Sycova-Mila Z; Mardiak J
    Klin Onkol; 2014; 27(6):429-33. PubMed ID: 25493582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomised Phase II trial of carboplatin and gemcitabine ± vandetanib in first-line treatment of patients with advanced urothelial cell cancer not suitable to receive cisplatin.
    Jones R; Crabb S; Chester J; Elliott T; Huddart R; Birtle A; Evans L; Lester J; Jagdev S; Casbard A; Huang C; Madden TA; Griffiths G
    BJU Int; 2020 Aug; 126(2):292-299. PubMed ID: 32336008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gemcitabine/nab-paclitaxel vs gemcitabine/carboplatin for advanced urothelial carcinoma.
    An X; Xue C; Chen M; Ni M; Ma H; Tian L; Huang R; Li X; Ye Y; Qin T; Dong P; Li Z; Peng J; Yao K; Zhou F; Liu Z; Shi Y
    BJU Int; 2024 Jul; 134(1):63-71. PubMed ID: 38009394
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial.
    Birtle A; Johnson M; Chester J; Jones R; Dolling D; Bryan RT; Harris C; Winterbottom A; Blacker A; Catto JWF; Chakraborti P; Donovan JL; Elliott PA; French A; Jagdev S; Jenkins B; Keeley FX; Kockelbergh R; Powles T; Wagstaff J; Wilson C; Todd R; Lewis R; Hall E
    Lancet; 2020 Apr; 395(10232):1268-1277. PubMed ID: 32145825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gemcitabine and carboplatin in advanced transitional cell carcinoma of the urinary tract: an alternative therapy.
    Nogué-Aliguer M; Carles J; Arrivi A; Juan O; Alonso L; Font A; Mellado B; Garrido P; Sáenz A;
    Cancer; 2003 May; 97(9):2180-6. PubMed ID: 12712469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II trial of combination nab-paclitaxel, carboplatin and gemcitabine in first line therapy of advanced urothelial carcinoma.
    Alva A; Daignault S; Smith DC; Hussain M
    Invest New Drugs; 2014 Feb; 32(1):188-94. PubMed ID: 24318901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biweekly carboplatin/gemcitabine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: report of efficacy, quality of life and geriatric assessment.
    Bamias A; Lainakis G; Kastritis E; Antoniou N; Alivizatos G; Koureas A; Chrisofos M; Skolarikos A; Karayiotis E; Dimopoulos MA
    Oncology; 2007; 73(5-6):290-7. PubMed ID: 18477854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gemcitabine for unresectable, locally advanced or metastatic bladder cancer.
    Shelley M; Cleves A; Wilt TJ; Mason M
    Cochrane Database Syst Rev; 2011 Apr; (4):CD008976. PubMed ID: 21491413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gemcitabine and carboplatin combination as first-line treatment in elderly patients and those unfit for cisplatin-based chemotherapy with advanced bladder carcinoma: Phase II study of the Hellenic Co-operative Oncology Group.
    Linardou H; Aravantinos G; Efstathiou E; Kalofonos C; Anagnostopoulos A; Deliveliotis C; Bafaloukos D; Athanasios Dimopoulos M; Bamias A;
    Urology; 2004 Sep; 64(3):479-84. PubMed ID: 15351574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carboplatin versus two doses of cisplatin in combination with gemcitabine in the treatment of advanced non-small-cell lung cancer: Results from a British Thoracic Oncology Group randomised phase III trial.
    Ferry D; Billingham L; Jarrett H; Dunlop D; Woll PJ; Nicolson M; Shah R; Thompson J; Spicer J; Muthukumar D; Skailes G; Leonard P; Chetiyawardana AD; Wells P; Lewanski C; Crosse B; Hill M; Gaunt P; O'Byrne K
    Eur J Cancer; 2017 Sep; 83():302-312. PubMed ID: 28780466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [First line therapy for local advanced or metastatic urothelial cell carcinoma: randomized phase II study to investigate the combination of vinflunine with gemcitabine and vinflunine with carboplatin in patients unfit for cisplatin therapy with advanced or metastatic urothelial cell carcinoma (JASINT-1 - AB 38/11) of AUO].
    Rexer H
    Urologe A; 2011 Aug; 50(8):974-6. PubMed ID: 21779884
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.